• About
  • Advertise
  • Contact
Friday, May 16, 2025
Manhattan Tribune
  • Home
  • World
  • International
  • Wall Street
  • Business
  • Health
No Result
View All Result
  • Home
  • World
  • International
  • Wall Street
  • Business
  • Health
No Result
View All Result
Manhattan Tribune
No Result
View All Result
Home Health

Known anti-obesity drug could improve heart health

manhattantribune.com by manhattantribune.com
25 November 2023
in Health
0
Known anti-obesity drug could improve heart health
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


Semaglutide, present in Ozempic and Wegovy, is effective in weight loss. In addition, it would reduce major cardiovascular events by 20% in overweight or obese patients without a history of diabetes.

This will also interest you

(ON VIDEO) Naturally yours: is obesity a societal disease? Can our modern society influence diseases like obesity? In this video, the nutritionist…

In addition to its possible anti-cancer properties, researchers attribute protective effects to Ozempic and Wegovy against cardiovascular risk. These two antidiabetic drugs also used for weight loss contain the same active ingredient, semaglutide.

“ We know that overweight and obesity increase the risk of cardiovascular events. However, while the reduction of cardiovascular diseases by the treatment ofhypercholesterolemiahypercholesterolemiaof the’high blood pressurehigh blood pressure and diabetesdiabetes is a common practice, the concept of treating obesity to reduce cardiovascular complications has been hampered “, explained Michael Lincoff, co-author of a new study published in the New England Journal of Medicine.

A possible route to treating the harmful effects of obesity and diabetes

The test Select included more than 17,000 participants over the age of 45 who had pre-existing cardiovascular disease and a BMI of at least 27, but who had no history of diabetes. The results show that a weekly dose of 2.4 mg of semaglutide allows a 20% reduction in major adverse cardiovascular events (cardiovascular death, myocardial infarctionmyocardial infarction And StrokeStroke non-fatal) in these overweight or obese patients not diabeticsdiabeticscompared to a placeboplacebo. Follow-up lasted 39.8 months in total.

One limitation of the trial is that it only included patients with pre-existing cardiovascular diseases and events. The effects of treatment on overweight or obese people without a history of cardiovascular disease were therefore not measured.

Of course, the drug’s beneficial effects on heart health were mediated by attractive weight loss. Improve your lifestyle through a balanced diet and activity physicalphysical Regular exercise is therefore important for the health of your heart.

Tags: antiobesitydrughealthheartimprove
Previous Post

Truce in the Gaza Strip: thousands of Gazans try to return home

Next Post

FIRST discovery of dozens of new giant radio galaxies

Next Post
FIRST discovery of dozens of new giant radio galaxies

FIRST discovery of dozens of new giant radio galaxies

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Category

  • Blog
  • Business
  • Health
  • International
  • National
  • Science
  • Sports
  • Wall Street
  • World
  • About
  • Advertise
  • Contact

© 2023 Manhattan Tribune -By Millennium Press

No Result
View All Result
  • Home
  • International
  • World
  • Business
  • Science
  • National
  • Sports

© 2023 Manhattan Tribune -By Millennium Press